ANALYSIS: Life After Pfizer Will See Allergan Make Waves In Alzheimer's
This article was originally published in Scrip
Executive Summary
With patent expiries threatening Allergan plc's position as a current leader in the Alzheimer's disease market, and following the failed attempt at gaining direct access to Pfizer Inc.'s resources, Allergan's decision to partner up with Heptares Therapeutics (subsidiary of Sosei Group Corporation) can help reinforce its commitment to developing treatments for Alzheimer's and other neurological disorders.